Categories: News

Fossil launches its first smartwatch on the Qualcomm Snapdragon Wear 3100 platform

Fossil Sport is the lightest, most colorful, sporty offering in Fossil’s wearable portfolioNovember 8, 2018—Richardson, TX It is with great excitement that Fossil brand announces its newest addition to our wearables assortment: the Fossil Sport Smartwatch. Based on the recently launched Qualcomm® Snapdragon Wear™ 3100 platform and the newly redesigned Wear OS by Google™, this watch boasts several new technology features including extended battery life, a new battery saving mode, enhanced ambient mode, integrated heart…

Source: RealWire

user

Share
Published by
user
7 years ago

Recent Posts

Owlet Launches TGA-Approved Dream Sock™ in Australia & New Zealand, Expanding International Footprint and Bringing Trusted Pediatric Health Monitoring to More Families Worldwide

TGA approval enables regional launch of Owlet’s clinically validated, award-winning infant health monitor; Owlet360™ subscription…

10 minutes ago

CONMED Corporation Announces Strategic Exit from Gastroenterology Product Lines

Concludes Distribution Agreement with Gore® for VIABIL® in the United States and Canada, Effective January…

11 minutes ago

TriSalus Life Sciences to Host Virtual KOL Event to Discuss the TriNav Infusion System for the Treatment of Symptomatic Thyroid Disease on December 15, 2025

WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology company…

12 minutes ago

Accendatech US comments on the recent setback in phase 2 study to evaluate STAT3 as therapeutic target and other drug development strategies such as AI and precision medicine to treat patients with IPF

BOSTON, Dec. 05, 2025 (GLOBE NEWSWIRE) -- A recent setback due to unexpected safety concern…

17 minutes ago

Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting

—Long-term Phase 1/2a and open label extension (OLE) data for zorevunersen on top of standard…

17 minutes ago

Xenon Showcases New 48-Month Azetukalner OLE Study Data in Epilepsy at AES 2025

Monthly reductions in seizure frequency of 90.9% among participants treated for ≥48 months in the…

17 minutes ago